Table 2.
Basal Characteristics and Test Results of the Patient Group (n = 171)
| Baseline Characteristics | AI (n = 59) | Non-AI (n = 112) |
|---|---|---|
| Age, years | 56.9 ± 14.2 (25–80) | 56.6 ± 12.4 (19–89) |
| Sex | M = 39; F = 20 | M = 43; F = 69 |
| eGFR,a mL/min/1.73m2 | 92.1 ± 29.5 (36–153) | 92.5 ± 25.7 (37–169) |
| Chronic liver disease | 1 | 1 |
| TSH, mIU/L/fT4, pmol/L | 1.43 ± 1.34/13.5 ± 3.4 | 1.28 ± 0.82/13.0 ± 1.8 |
| Clinical feature | 24 (40.7%) | 31 (27.7%) |
| Postural hypotension | 1 | 1 |
| Dizziness/fatigue/weight loss | 19 | 25 |
| Neurologic symptoms | 2 | 1 |
| Gastrointestinal symptoms | 2 | 1 |
| Cushingoid | 0 | 1 |
| Hypoglycemia | 0 | 2 |
| Electrolyte disturbance | 11 (18.6%) | 7 (6.3%) |
| Hyponatremia | 9 | 6 |
| Hyperkalemia | 2 | 1 |
| Suprasellar/sellar disease | 34 (57.6%) | 90 (80.4%) |
| A. Disease | ||
| Nonfunctioning pituitary adenoma | 13 | 48 |
| Acromegaly | 3 | 12 |
| Cushing disease | 1 | 0 |
| Prolactinoma | 2 | 3 |
| Craniopharyngioma | 3 | 3 |
| Pituitary apoplexy | 3 | 5 |
| Empty sellar syndrome | 2 | 5 |
| Nasopharyngeal carcinoma | 1 | 5 |
| Others | 6 | 9 |
| B. Intervention | ||
| Brain surgery | 22 (37.3%) | 66 (58.9%) |
| Radiotherapy | 9 (15.3%) | 16 (14.3%) |
| Gamma knife | 10 (16.9%) | 22 (19.6%) |
| C. Complications | ||
| Visual impairment | 16 (27.1%) | 38 (33.9%) |
| Hypopituitarism other than cortisol | 26 (44.0%) | 41 (36.6%) |
| Cranial diabetes insipidus | 6 (10.2%) | 12 (10.7%) |
| Use of exogenous steroid | 20 (33.9%) | 12 (10.7%) |
| Adrenalectomy for Cushing syndrome | 2 (3.4%) | 2 (1.8%) |
| Addison disease | 1 (1.7%) | 0 (0%) |
| Test results | ||
| Serum cortisol, nmol/L | ||
| Basal (at 0 min) | 106.1 ± 80.7 (<28–320) | 264.1 ± 88.4 (116–532) |
| Peak (at 30 or 60 min) | 203.2 ± 121.6 (<28–366) | 486.8 ± 76.7 (376–682) |
| Salivary cortisol, nmol/L | ||
| Basal (at 0 min) | 2.0 ± 2.1 (<0.5–10) | 4.7 ± 3.0 (1.2–19) |
| Peak (at 30 or 60 min) | 5.9 ± 6.9 (<0.5–33) | 20.9 ± 10.1 (5.3–52) |
| Salivary cortisone, nmol/L | ||
| Basal (at 0 min) | 9.6 ± 9.8 (<0.5–42) | 24.5 ± 10.5 (8.4–61) |
| Peak (at 30 or 60 min) | 18.9 ± 16.2 (<0.5–62) | 54.0 ± 17.3 (17–111) |
| Serum proteins | ||
| CBG, μg /mLb | 29.8 ± 7.6 (10.2–52.3) | 32.0 ± 6.0 (19.4–53.0) |
| Albumin, g/L | 41.8 ± 3.7 (31–49) | 43.6 ± 3.2 (29–51) |
Continuous data are expressed as mean ± SD (range) and are rounded to 1 decimal place, except for TSH, which is rounded to 2 decimal places. Integral values represent number of patients (percentage) unless otherwise specified.
Abbreviation: eGFR, estimated glomerular filtration rate.
a
Calculated by the abbreviated modification of diet in renal disease equation: 186 × (Creatinine/88.4)−1.154 × (Age)−0.203 × (0.742 if female).
b
Divide by 52 to convert μg/mL to μmol/L, as the relative molecular mass of CBG is 52 kDa.